Dr. Brufsky on the FDA Approval of Olaparib in BRCA+ Breast Cancer

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses the FDA approval of olaparib (Lynparza) for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic settings.

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses the FDA approval of olaparib (Lynparza) for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic settings.

Related Content:

OncLive TVBreast CancerPrecision Medicine in Oncology®
Dr Garrot on Lutetium Lu 177 Vipivotide Tetraxetan in Older Patients with MCRPC
BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors
Dr Delforge on the Rationale for CARTITUDE-4 in Lenalidomide-Refractory Myeloma